Clover Health Investments Corp. (CLOV)

NASDAQHealth CareMedical - Healthcare PlansSnapshot 2026-10-23

$4.60-2.75%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge Clover Health Investments Corp.’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
FY 2026 · Q4
Revenue	—	723.47M
EPS	—	-0.045
FY 2026 · Annual
Revenue	$2.92B–$3B	2.95B
EPS	—	0.056
EBITDA	$70M–$85Mnon-GAAP	—
FY 2027 · Annual
Revenue	—

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Achieve GAAP net income between $0M and $20M in 2026	Clover Health is improving profitability with GAAP net income expected between $0M and $20M in 2026.	Improving	GAAP net income falls below $0 million in 2026	Net income: $28.001M FY2026-Q2; GAAP. Published target: >=0 USD million net income in FY26. Target period is not explicitly aligned with this observation. Source published Aug 7, 202628,001,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 9d5ae7b3-380e-454e-bc28-a28df1da4e6b. Source status: eligible. Compare required operating outcomes

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS: comparable history unavailable.

FY2027 revenue: comparable history unavailable.

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	Unavailable	Unavailable	1 / 3
2026-07-25	Unavailable	Unavailable	1 / 3
2026-07-26	Unavailable	Unavailable	1 / 3
2026-07-27	Unavailable	Unavailable	1 / 3
2026-07-28	Unavailable	Unavailable	1 / 3
2026-07-29	Unavailable	Unavailable

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Achieve GAAP net income between $0M and $20M in 2026Net income: $28.001M
Grow Medicare Advantage membership by 46% to 154,000-158,000 in 2026Direct metric needs a verified mapping
Increase total revenues to $2.81B-$2.92B in 2026, 49% growth YoYRevenue: $743.167M

Next proof point

Nov 4, 2026

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

2.3%Typical daily move · historical

Downside history

-55.5%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Clover Health Investments Corp. outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

This is a high-growth healthcare business with an emerging profitability story, rather than a proven durable compounder. The multi-year view is intact, but confidence is medium because recent results are strong while the business still has a loss-making profile in the evidence snapshot.

What's priced into Clover Health Investments Corp.

The valuation evidence describes CLOV as cheap versus peers, with the market’s expectations below the model’s view, though confidence in that comparison is low. The priced-in tag is justified and fragility is low, so the snapshot does not point to an unusually fragile expectations setup.

What the fundamentals likely do

Near term, revenue and Medicare Advantage membership growth are tracking ahead of management’s stated priorities, and CLOV reported positive GAAP net income in both 2026’s first and second quarters. Management’s full-year 2026 guidance still implies positive net income, but profitability execution remains mixed and the company has a history of misses. The risk label has eased from high to elevated, but remains elevated.

What Clover Health Investments Corp. hinges on

The multi-year thesis hinges on sustaining growth while delivering positive full-year GAAP net income in 2026. A guidance cut after the recent raise would damage credibility, while continued strength from healthcare peers could support sector momentum. A further weakening jobs report could add pressure to cyclical and healthcare businesses.

Bottom line

Over the next one to three years, CLOV’s case rests on converting strong membership and revenue growth into lasting profitability. The thesis remains intact, but execution and guidance credibility are key uncertainties. Not investment advice.

Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.

EPS	—	0.1

2026-07-30	Unavailable	Unavailable	1 / 2

2026-07-31	Unavailable	Unavailable	1 / 3

2026-08-01	Unavailable	Unavailable	1 / 3

2026-08-02	Unavailable	Unavailable	1 / 3

2026-08-03	Unavailable	Unavailable	1 / 2

2026-08-04	Unavailable	Unavailable	1 / 3

2026-08-05	Unavailable	Unavailable	1 / 3

2026-08-06	Unavailable	Unavailable	1 / 2

2026-08-07	Unavailable	Unavailable	1 / 2

2026-08-08	Unavailable	Unavailable	1 / 2

2026-08-09	Unavailable	Unavailable	1 / 3

2026-08-10	Unavailable	Unavailable	1 / 3

2026-08-11	Unavailable	Unavailable	1 / 3

2026-08-12	Unavailable	Unavailable	1 / 2

2026-08-13	Unavailable	Unavailable	1 / 3

2026-08-14	Unavailable	Unavailable	1 / 2

2026-08-15	Unavailable	Unavailable	1 / 2

2026-08-16	Unavailable	Unavailable	1 / 2

2026-08-17	Unavailable	Unavailable	1 / 2

2026-08-18	Unavailable	Unavailable	1 / 2

2026-08-19	Unavailable	Unavailable	1 / 2

2026-08-20	Unavailable	Unavailable	1 / 2

2026-08-21	Unavailable	Unavailable	1 / 2

2026-08-22	Unavailable	Unavailable	1 / 2

2026-08-23	Unavailable	Unavailable	1 / 2

2026-08-24	Unavailable	Unavailable	1 / 2

2026-08-25	Unavailable	Unavailable	1 / 2

2026-08-26	Unavailable	Unavailable	1 / 2

2026-08-27	Unavailable	Unavailable	1 / 2

2026-08-28	Unavailable	Unavailable	1 / 2

2026-08-29	Unavailable	Unavailable	1 / 2

2026-08-30	Unavailable	Unavailable	1 / 2

2026-08-31	Unavailable	Unavailable	1 / 2

2026-09-01	Unavailable	Unavailable	1 / 2

2026-09-02	Unavailable	Unavailable	1 / 2

2026-09-03	Unavailable	Unavailable	1 / 2

2026-09-04	Unavailable	Unavailable	1 / 2

2026-09-05	Unavailable	Unavailable	1 / 2

2026-09-06	Unavailable	Unavailable	1 / 2

2026-09-07	Unavailable	Unavailable	1 / 2

2026-09-08	Unavailable	Unavailable	1 / 2

2026-09-09	Unavailable	Unavailable	1 / 2

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold
2026-05-01	1	2
2026-06-01	1	2
2026-07-01	1	2
2026-08-01	1	2
2026-09-01	2	2
2026-10-01	2	2

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 2 Buy / Strong Buy · 2 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades0 maintains

Recent actions · Sep 25–Oct 24 · 0 recorded

What could strengthen or challenge Clover Health Investments Corp.’s outlook?

What the Thesis Depends On

Incoming Evidence

Expectations trend

Outlook in Brief

What's improving

Still unresolved / key risks

Next proof point

Historical risk context

Clover Health Investments Corp. outlook in detail

What kind of bet this is

What's priced into Clover Health Investments Corp.

What the fundamentals likely do

What Clover Health Investments Corp. hinges on

Bottom line

Analyst view

Price-target changes

Bottom line